Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
dhbuzz Member Profile
 
Followed By 9
Posts 2,775
Boards Moderated 0
Alias Born 03/01/19
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/8/2021 1:05:46 PM
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire Inc. - 1/4/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 7:02:09 AM
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 12/17/2020 6:30:00 AM
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire - 12/9/2020 3:49:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 12:31:08 PM
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire Inc. - 12/4/2020 11:30:00 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy S... GlobeNewswire Inc. - 11/23/2020 11:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2020 7:17:39 AM
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/9/2020 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:16:27 PM
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the... GlobeNewswire Inc. - 10/15/2020 3:06:10 PM
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder... GlobeNewswire Inc. - 10/15/2020 3:05:10 PM
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACA... GlobeNewswire Inc. - 10/8/2020 8:32:10 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16... GlobeNewswire Inc. - 10/8/2020 8:30:10 AM
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire Inc. - 9/17/2020 1:55:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 7:02:02 AM
Zynerba Pharmaceuticals Provides Update on Recent Milestones GlobeNewswire Inc. - 9/14/2020 6:55:10 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 9/10/2020 7:30:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 9:28:55 AM
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 8/10/2020 6:45:10 AM
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Con... GlobeNewswire Inc. - 7/22/2020 6:50:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 10:43:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/30/2020 6:59:54 AM
dhbuzz   Thursday, 09/17/20 02:37:19 PM
Re: None
Post # of 2639 
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
September 17 2020 - 01:55PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems.
“Zynerba is committed to developing Zygel™ CBD gel in certain rare and near-rare conditions, including 22q, for which there is an urgent need for new, innovative therapeutics,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We are pleased that the FDA shares our sense of urgency regarding the development of effective therapeutics in this important patient population. The receipt of this designation represents another important milestone for us, and we look forward to working closely with the FDA to develop Zygel in pediatric and adolescent patients with 22q as expeditiously as possible.”

About Orphan Drug Designation
Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat rare diseases or conditions that affect fewer than 200,000 individuals in the U.S. The first NDA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA orphan drug designation is entitled to various incentives of the ODA, including tax credits for qualified clinical testing, waiver of new drug application (NDA) / biologics license application (BLA) user fees, and eligibility for a seven-year exclusive marketing period for that drug and use upon marketing approval.

About 22q11.2 Deletion Syndrome (22q)
As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome. The deletion occurs near the middle of the chromosome at a location designated q11.2. It is considered a mid-line condition, with physical symptoms including characteristic palate abnormalities, heart defects, immune dysfunction, and esophageal / GI issues, as well as debilitating neuropsychiatric and behavioral challenges. Anxiety is among the most common neuropsychiatric symptoms of 22q and researchers have found that for children with 22q, anxiety is linked to poorer adaptive behaviors such as self-care and communication skills that affect daily life. Children with 22q also experience withdrawn behavior, ADHD, cognitive impairment, and autism spectrum disorder that affect communication and social interaction. Later in life, they are at an increased risk of developing mental illnesses such as schizophrenia. It is estimated that 22q occurs in between one in 3,000 and one in 6,000 live births, suggesting that there are approximately 81,000 people living with 22q in the U.S.

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We ar

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences